Results 241 to 250 of about 12,993,017 (350)

Study on the improvement of electroencephalogram signal characteristics in stroke patients by edaravone dexborneol. [PDF]

Front Neurosci
Zhang S, Jiao H.
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Barriers and facilitators in physical activity among youth with cerebral palsy in Sweden: A qualitative study. [PDF]

PLoS One
Degerstedt F, Keisu BI, Björklund M, Enberg B.   +3 more
europepmc   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Mechanisms that create a sequence of feeding-related behaviors in the mollusk <i>Aplysia</i>. [PDF]

J Neurophysiol
Evans CG, Barry MA, Chen Q, Reaver CN, Patel PR, Chestek CA, Perkins MH, Jing J, Cropper EC.   +8 more
europepmc   +1 more source

The Emerging Parkinson's Disease Oxylipin‐Ome

Advanced Science, EarlyView.
ABSTRACT Parkinson Disease (PD) is increasingly considered a proteinopathy and lipidopathy. This proteinopathy+lipidopathy paradigm has been further refined to a fatty acid (FA)‐opathy, centering dysregulated FA metabolism as fundamental in PD lipid dysfunction.
Julia C. Kelliher, Saranna Fanning
wiley   +1 more source

The Cerebrovascular Reactivity Adjusted Fractional Amplitude of Low-Frequency Fluctuations Abnormalities in Middle Cerebral Artery Stenosis and Occlusive Disease. [PDF]

Transl Stroke Res
Zhang L, Wang L, Tang X, Zhu Y, Wang R, Ding Z.   +5 more
europepmc   +1 more source

NIR‐II Imaging‐Guided Photothermal Activation of a TRPV4‐Targeted Nanoplatform Delivering Cycloastragenol to Promote Microglia Reprogramming and α‐Synuclein Clearance in Parkinson's Disease

Advanced Science, EarlyView.
ABSTRACT Current therapies for Parkinson's disease (PD) fail to concurrently address α‐synuclein (α‐syn) aggregation and microglia‐mediated neuroinflammation. Herein, we engineer a near‐infrared‐II (NIR‐II) phototheranostic nanoplatform, CAG/FD1080@MM‐aTRPV4, for synergistic regulation of microglial function and real‐time monitoring of PD pathology. We
Hsuan Lo, Linjuan Feng, Shiying Li, Lik Hang Hugo Tse, Xuehan Wang, Xingyang Zhao, Shaoheng Ma, Xin Li, Yanjuan Gu, Wing‐Tak Wong   +9 more
wiley   +1 more source

A perspective: PLA2G4A as drug target for vascular inflammation in Alzheimer's disease. [PDF]

Alzheimers Dement
Kanwal A, Kerman BE, Wang S, Camey K, Li B, Flores-Aguilar L, Ali N, McIntire LB, Shu CA, Louie SG, Head E, Arvanitakis Z, Yassine HN.   +12 more
europepmc   +1 more source

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

Advanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong, Wenting Hui, Sai Qiao, Qifeng Ji, Miao Liu, Bangle Zhang, Daozhou Liu, Yumei Wu, Siyuan Zhou   +8 more
wiley   +1 more source